How the EMA has calculated that the benefits of vaccinating with Astrazaneca far outweigh the risks by age group

No treatment or vaccine is risk-free. So the key question is whether it does more good than bad. Regarding the AstraZeneca vaccineBoth the MHRA and EMA reviews reaffirm that the benefits continue to far outweigh the risks.

However, the risks are not the same for all age groups, so the cost-benefit calculation varies (although in all cases it is always favorably inclined towards profits).

Read more